Sarah Dakar Joins Jay Pharma as Vice President, Product DevelopmentFebruary 18, 2020
Jay Pharma Inc., a company dedicated to developing innovative, evidence-based medicines to address unmet patient needs in cancer care, today announced that Sarah Dakar has joined Jay Pharma’s leadership team as Vice President, Product Development. In her new role, Ms. Dakar will oversee the development and formulation of novel products, including the development of science-backed skincare products utilizing cannabidiol (“CBD”) and other evidence-based ingredients.
With over a decade of experience creating and marketing corrective skincare products used by some of the world’s most famous faces and tastemakers, Ms. Dakar is now bringing her passion, vision, and commitment to excellence to develop a new line of Jay Pharma topical and wellness products that utilize the unique beneficial properties of CBD, as well as other phytocannabinoids and terpene blends.
Ms. Dakar has spent the last three years formulating skincare products alongside the world’s leading cannabinoid researchers, creating proprietary complexes with CBD, CBG, CBN, and CBC in an effort to help patients with common skincare issues. She holds certifications as a CBD Consultant and Phytocannabinoid Chemistry and Cannabinoid Isolation Specialist from the CBD Industry Association.
Previously, Ms. Dakar served as Vice President and Beauty Director of the corrective, prestige skincare brands Sonya Dakar Skincare, UltraLuxe Skincare, and HappyMe, where she supervised key aspects of brand building and marketing. Sarah has acted as a brand spokesperson across numerous media platforms, making television appearances and writing “Sarah’s Secrets,” a popular recurring blog for the Huffington Post. Brand awards include Elle Top 5, Marie Claire Best 15 Products of All Time, Latina Men’s Health, and Allure Magazine’s Best Zit cream (two years in a row).
“Ms. Dakar is a skincare product development expert and has a track record of introducing unique and innovative products,” said Dave Johnson, who plans to join Jay Pharma as Chairman and CEO upon the closing of the Ameri merger transaction. “Ms. Dakar has a bold vision and she’s working tirelessly to improve the standard of care for patients. With Ms. Dakar’s guidance, we plan to introduce a novel line of cannabinoid skincare products in 2020.”
“I’m impressed with the Jay Pharma team and its high-level scientific leadership,” said Ms. Dakar. “Together, we are working to improve the quality of life of persons suffering from the side effects of cancer and cancer treatment. We are focused first on radiodermatitis and neuropathy – topical CBD and other cannabinoid formulations have emerged as attractive potential options for the prevention or mitigation of symptoms associated with these conditions. I look forward to taking the next steps to advance these products and others.
About Jay Pharma
Jay Pharma is dedicated to developing innovative, evidence-based medicines and combination therapies to address unmet needs in cancer care. Our mission is to improve the lives of patients suffering from cancer, initially by developing products for people dealing with the side effects of cancer and cancer treatments, and longer term by advancing a pipeline of novel combination therapies as an adjunct to standard of care cancer treatments.
This press release contains certain “forward-looking statements”. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Jay Pharma. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Jay Pharma cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Jay Pharma will be not be able to obtain market adoption of its products, Jay Pharma will not obtain appropriate or necessary governmental approvals to market these or other potential products, Jay Pharma may not be able to obtain anticipated funding for its development projects or other needed funding, and Jay Pharma may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Jay Pharma does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.